OrbusNeich Receives “Service and Innovative Product Awards 2024 – Medical Device Service Award” Continues to Improve Quality of Life of Patients Through Innovative Technologies

(Hong Kong, July 8, 2024) – OrbusNeich Medical Group Holdings Limited (“OrbusNeich” or the “Group”; stock code: 6929), a major global medical device manufacturer specializing in interventional devices for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures, has won the “Medical Device Service Award” at Service and Innovative Product Awards 2024, organized by a renowned Hong Kong financial magazine, Capital Magazine. The award is in recognition of the Group’s efforts in introducing and renewing innovative and comprehensive endovascular and structural heart disease intervention solutions, which have consistently improved the quality of life for numerous patients globally and cater to the public’s demand for health and medical services.

Mr. David Chien, Chairman, Executive Director and Chief Executive Officer of OrbusNeich, said, “Since its establishment, OrbusNeich has been committed to product innovation. It currently holds more than 240 licensed patents and published patent applications in key jurisdictions around the world, as well as over 40 approved products that have the potential to save lives and improve the quality of life for vascular disease patients in over 70 countries and regions. Notably, the Group has added a number of CE-marked products in the past year, which not only enhance its ability to treat lesions, but also address the demand from doctors and patients for ‘leave nothing behind’ in PCI and PTA procedures. We are deeply honored to be recognized for our technological innovation in medical devices and our persistence in meeting the medical needs of the society. Moving forward, we will continue to strive for excellence in providing patients with advanced and diverse intervention solutions, driven by a steadfast commitment to safeguarding public health and well-being.”

Innovative products and high-quality customer service are the keys to success in the market. The “Service and Innovative Product Awards” organized by Capital Magazine aims to recognize companies dedicated to providing quality services and products to their customers, commend their outstanding achievements in the industry and their efforts in continuously improving their service standards, and encourage companies to strive for excellence and sustain their good performance.

Mr. Jason Chen, Executive Director and Chief Financial Officer of OrbusNeich (right), accepts the “Service and Innovative Product Award 2024” from Capital Magazine on behalf of the Group.

－ End －

About OrbusNeich Medical Group Holdings Limited
OrbusNeich is a major global medical device manufacturer specializing in interventional devices for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures. Headquartered in Hong Kong, China, OrbusNeich sells its products in more than 70 countries and regions worldwide. It is also actively expanding into neuro vascular intervention and structural heart disease. As at December 31, 2023, OrbusNeich has more than 240 granted patents and published patent applications worldwide. Its in-house R&D team has more than two decades of product development experience and has developed world-leading proprietary technologies.